• About
    • Our Story
    • Management
    • Board of Directors
  • Science
  • Pipeline
    • BH-30643
    • BH-30236
    • Posters and Presentations
  • Clinical Trials
  • News
  • Careers
  • Contact
  • Menu Menu

About Us

We are building on our team’s proven track record of multiple approved therapies that have delivered transformational patient outcomes.

Learn More
scientist in lab
working in a lab

Science

Combining a deep understanding of disease and protein dynamics with our structure-based rational drug design expertise, we identify the specific structural liabilities that limit existing therapies or approaches, and then design novel chemical scaffolds to directly address these limitations.

Learn More

Pipeline

Medicines built from the ground up that aim to address the limitations of existing therapies.

Learn More

Clinical Trials

Explore our clinical trials and learn about how you can participate.

Learn More

Latest News

Learn More

BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026

June 10, 2026/in Press Releases/by David Anderson

June 11, 2026

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 David Anderson /wp-content/uploads/BlossomHill-Logo_FullColor.svg David Anderson2026-06-10 12:33:202026-06-10 12:36:54BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026

BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting

May 21, 2026/in Press Releases/by David Anderson

May 21, 2026

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 David Anderson /wp-content/uploads/BlossomHill-Logo_FullColor.svg David Anderson2026-05-21 12:47:572026-06-10 12:34:04BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting

BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid

May 19, 2026/in Press Releases/by David Anderson

May 20, 2026

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 David Anderson /wp-content/uploads/BlossomHill-Logo_FullColor.svg David Anderson2026-05-19 18:19:142026-06-10 12:34:14BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid

© 2026 BlossomHill Therapeutics, Inc. | Terms of Service | Privacy Notice
Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only